Published in Cancer Res on March 15, 2007
MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem (2008) 4.56
Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res (2008) 3.16
MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem (2009) 3.16
MicroRNA-140 acts as a liver tumor suppressor by controlling NF-κB activity by directly targeting DNA methyltransferase 1 (Dnmt1) expression. Hepatology (2013) 1.09
Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics (2009) 0.96
Differential expression of metallothioneins (MTs) 1, 2, and 3 in response to zinc treatment in human prostate normal and malignant cells and tissues. Mol Cancer (2008) 0.96
Loss of metallothionein predisposes mice to diethylnitrosamine-induced hepatocarcinogenesis by activating NF-kappaB target genes. Cancer Res (2010) 0.94
Nerve growth factor blocks thapsigargin-induced apoptosis at the level of the mitochondrion via regulation of Bim. J Cell Mol Med (2008) 0.94
Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivity. Mol Endocrinol (2008) 0.93
Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology (2016) 0.91
Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma. Gynecol Oncol (2012) 0.89
Triptolide inhibits IL-12/IL-23 expression in APCs via CCAAT/enhancer-binding protein alpha. J Immunol (2010) 0.89
Peretinoin, an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma. BMC Cancer (2013) 0.89
MT1M and MT1G promoter methylation as biomarkers for hepatocellular carcinoma. World J Gastroenterol (2014) 0.80
A novel crosstalk between TLR4- and NOD2-mediated signaling in the regulation of intestinal inflammation. Sci Rep (2015) 0.80
Reduced expression of C/EBP alpha protein in hepatocellular carcinoma is associated with advanced tumor stage and shortened patient survival. J Cancer Res Clin Oncol (2008) 0.80
The GSK3/Shaggy-Like Kinase ASKα Contributes to Pattern-Triggered Immunity. Plant Physiol (2016) 0.79
Heavy metal-induced metallothionein expression is regulated by specific protein phosphatase 2A complexes. J Biol Chem (2014) 0.78
The metal-responsive transcription factor-1 protein is elevated in human tumors. Cancer Biol Ther (2010) 0.77
IL-17 promotes keratinocyte proliferation via the downregulation of C/EBPα. Exp Ther Med (2015) 0.77
Zinc-induced upregulation of metallothionein (MT)-2A is predicted by gene expression of zinc transporters in healthy adults. Genes Nutr (2015) 0.77
Mutant thyroid hormone receptors (TRs) isolated from distinct cancer types display distinct target gene specificities: a unique regulatory repertoire associated with two renal clear cell carcinomas. Mol Endocrinol (2011) 0.77
Epigenetic Upregulation of Metallothionein 2A by Diallyl Trisulfide Enhances Chemosensitivity of Human Gastric Cancer Cells to Docetaxel Through Attenuating NF-κB Activation. Antioxid Redox Signal (2016) 0.76
Novel Insights into the Molecular Mechanism of Action of DNA Hypomethylating Agents: Role of Protein Kinase C δ in Decitabine-Induced Degradation of DNA Methyltransferase 1. Genes Cancer (2012) 0.76
Hepatotoxic potential of asarones: in vitro evaluation of hepatotoxicity and quantitative determination in herbal products. Front Pharmacol (2015) 0.75
Comments to metallothionein as an anti-inflammatory mediator. Mediators Inflamm (2009) 0.75
Proliferative, structural and molecular features of the Mdx mouse prostate. Int J Exp Pathol (2010) 0.75
A tumor suppressor role for C/EBPα in solid tumors: more than fat and blood. Oncogene (2017) 0.75
A system for stable expression of short interfering RNAs in mammalian cells. Science (2002) 35.21
The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer (2002) 28.11
Gene expression profiles in normal and cancer cells. Science (1997) 9.65
Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev (2004) 3.91
Molecular viral oncology of hepatocellular carcinoma. Oncogene (2003) 3.58
Ras-dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase. Science (1995) 3.42
5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol (2005) 3.05
Regulation of metallothionein gene expression by oxidative stress and metal ions. Biochem Pharmacol (2000) 2.59
Molecular stop signs: regulation of cell-cycle arrest by C/EBP transcription factors. J Cell Sci (2005) 2.57
Environmental factors and risk for hepatocellular carcinoma. Gastroenterology (2004) 2.47
Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene (2006) 2.28
New therapies for hepatocellular carcinoma. Oncogene (2006) 2.05
Thiolate ligands in metallothionein confer redox activity on zinc clusters. Proc Natl Acad Sci U S A (1998) 2.01
Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res (2003) 1.94
Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. Oncogene (2006) 1.92
Glycogen synthase kinase 3 is an insulin-regulated C/EBPalpha kinase. Mol Cell Biol (1999) 1.92
Induction of a new metallothionein isoform (MT-IV) occurs during differentiation of stratified squamous epithelia. Biochemistry (1994) 1.91
Mechanisms of disease: Inflammation and the origins of cancer. Nat Clin Pract Oncol (2005) 1.88
Expression profiling suggested a regulatory role of liver-enriched transcription factors in human hepatocellular carcinoma. Cancer Res (2001) 1.78
Simian virus 40 large tumor antigen-immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens. Proc Natl Acad Sci U S A (1993) 1.71
The transcription factor MTF-1 mediates metal regulation of the mouse ZnT1 gene. J Biol Chem (2000) 1.70
Inhibitors of histone deacetylase and DNA methyltransferase synergistically activate the methylated metallothionein I promoter by activating the transcription factor MTF-1 and forming an open chromatin structure. Mol Cell Biol (2002) 1.64
Phosphorylation of C/EBPalpha inhibits granulopoiesis. Mol Cell Biol (2004) 1.61
Liver tumors escape negative control of proliferation via PI3K/Akt-mediated block of C/EBP alpha growth inhibitory activity. Genes Dev (2004) 1.59
McBindall--a better name for CCAAT/enhancer binding proteins? Cell (2001) 1.55
New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene (2006) 1.52
DNA methyltransferase 3b regulates nerve growth factor-induced differentiation of PC12 cells by recruiting histone deacetylase 2. Mol Cell Biol (2005) 1.41
Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity. Oncogene (2006) 1.41
Suppression of metallothionein gene expression in a rat hepatoma because of promoter-specific DNA methylation. J Biol Chem (2000) 1.36
Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma. Int J Cancer (2003) 1.25
Treatment of hepatocellular carcinoma: is there an optimal strategy? Cancer Treat Rev (2003) 1.25
Recent studies on metallothionein: protection against toxicity of heavy metals and oxygen free radicals. Tohoku J Exp Med (2002) 1.24
Regulation of metallothionein gene expression. Prog Nucleic Acid Res Mol Biol (2001) 1.24
Cyclin D3 maintains growth-inhibitory activity of C/EBPalpha by stabilizing C/EBPalpha-cdk2 and C/EBPalpha-Brm complexes. Mol Cell Biol (2006) 1.22
Physical and functional interaction of DNA methyltransferase 3A with Mbd3 and Brg1 in mouse lymphosarcoma cells. Cancer Res (2005) 1.17
The antioxidant function of metallothionein in the heart. Proc Soc Exp Biol Med (1999) 1.15
Silencing of metallothionein-I gene in mouse lymphosarcoma cells by methylation. Oncogene (1999) 1.11
Analysis of promoter methylation and its role in silencing metallothionein I gene expression in tumor cells. Methods Enzymol (2002) 1.04
Phosphorylation is involved in the activation of metal-regulatory transcription factor 1 in response to metal ions. J Biol Chem (2001) 1.04
Hypermethylation of metallothionein-I promoter and suppression of its induction in cell lines overexpressing the large subunit of Ku protein. J Biol Chem (1999) 1.03
CCAAT/enhancer binding protein alpha knock-in mice exhibit early liver glycogen storage and reduced susceptibility to hepatocellular carcinoma. Cancer Res (2005) 1.00
Repeated cadmium exposures enhance the malignant progression of ensuing tumors in rats. Toxicol Sci (2000) 0.98
Immunohistochemical metallothionein expression in hepatocellular carcinoma: relation to tumor progression and chemoresistance to platinum agents. J Gastroenterol (2004) 0.96
The "metal transcription factor" MTF-1: biological facts and medical implications. Swiss Med Wkly (2001) 0.94
Down-regulated expression of the CCAAT/enhancer binding protein alpha and beta genes in human hepatocellular carcinoma: a possible prognostic marker. Anticancer Res (2003) 0.93
Metallothionein overexpression suppresses hepatic hyperplasia induced by hepatitis B surface antigen. Toxicol Appl Pharmacol (1999) 0.88
Hypersusceptibility to cisplatin carcinogenicity in metallothionein-I/II double knockout mice: production of hepatocellular carcinoma at clinically relevant doses. Int J Cancer (2006) 0.87
Metallothionein deficiency enhances skin carcinogenesis induced by 7,12-dimethylbenz[a]anthracene and 12-O-tetradecanoylphorbol-13-acetate in metallothionein-null mice. Carcinogenesis (2003) 0.86
A new diagnostic method for chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma based on serum metallothionein, copper, and zinc levels. Biol Pharm Bull (2002) 0.84
Immunohistochemical analysis of biliary tract lesions. Appl Immunohistochem Mol Morphol (2004) 0.84
MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology (2007) 13.20
Adipocyte differentiation from the inside out. Nat Rev Mol Cell Biol (2006) 11.36
TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell (2006) 7.49
p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol (2007) 6.87
MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem (2008) 4.56
Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A (2005) 4.48
Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res (2006) 4.26
Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem (2006) 4.15
Regulation of Wnt signaling during adipogenesis. J Biol Chem (2002) 3.94
Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res (2008) 3.16
MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem (2009) 3.16
Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest (2012) 3.14
5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol (2005) 3.05
Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem (2008) 3.00
Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation. J Biol Chem (2010) 2.99
MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg (2008) 2.86
Using molecular classification to predict gains in maximal aerobic capacity following endurance exercise training in humans. J Appl Physiol (1985) (2010) 2.74
Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis. Nat Commun (2012) 2.65
Microarray analyses during adipogenesis: understanding the effects of Wnt signaling on adipogenesis and the roles of liver X receptor alpha in adipocyte metabolism. Mol Cell Biol (2002) 2.44
Wnt10b inhibits development of white and brown adipose tissues. J Biol Chem (2004) 2.32
Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology (2009) 2.29
Role of human ribosomal RNA (rRNA) promoter methylation and of methyl-CpG-binding protein MBD2 in the suppression of rRNA gene expression. J Biol Chem (2003) 2.15
Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma. EMBO J (2007) 2.08
Fat-specific protein 27 regulates storage of triacylglycerol. J Biol Chem (2008) 2.07
Wnt signaling protects 3T3-L1 preadipocytes from apoptosis through induction of insulin-like growth factors. J Biol Chem (2002) 2.05
Adipose tissue stem cells meet preadipocyte commitment: going back to the future. J Lipid Res (2011) 1.94
Critical role for hypothalamic mTOR activity in energy balance. Cell Metab (2009) 1.90
Wnt signaling inhibits adipogenesis through beta-catenin-dependent and -independent mechanisms. J Biol Chem (2005) 1.85
Wnt6, Wnt10a and Wnt10b inhibit adipogenesis and stimulate osteoblastogenesis through a β-catenin-dependent mechanism. Bone (2011) 1.83
Roles for miRNA-378/378* in adipocyte gene expression and lipogenesis. Am J Physiol Endocrinol Metab (2010) 1.78
Wnt10b increases postnatal bone formation by enhancing osteoblast differentiation. J Bone Miner Res (2007) 1.77
The microRNA miR-8 is a conserved negative regulator of Wnt signaling. Proc Natl Acad Sci U S A (2008) 1.76
Immunohistochemistry staining for the mismatch repair proteins in the clinical care of patients with colorectal cancer. Genet Med (2009) 1.76
Wnt signaling promotes oncogenic transformation by inhibiting c-Myc-induced apoptosis. J Cell Biol (2002) 1.75
Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Arch Pathol Lab Med (2009) 1.67
Wnt10b inhibits obesity in ob/ob and agouti mice. Diabetes (2007) 1.65
Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomas. Oncogene (2003) 1.64
Inhibitors of histone deacetylase and DNA methyltransferase synergistically activate the methylated metallothionein I promoter by activating the transcription factor MTF-1 and forming an open chromatin structure. Mol Cell Biol (2002) 1.64
Phosphorylation of C/EBPalpha inhibits granulopoiesis. Mol Cell Biol (2004) 1.61
Marrow fat and bone--new perspectives. J Clin Endocrinol Metab (2013) 1.60
Somatic acquisition and signaling of TGFBR1*6A in cancer. JAMA (2005) 1.59
The embryonic stem cell transcription factors Oct-4 and FoxD3 interact to regulate endodermal-specific promoter expression. Proc Natl Acad Sci U S A (2002) 1.52
Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma? Arthritis Rheum (2011) 1.51
Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer. Proc Natl Acad Sci U S A (2004) 1.49
Wnt10b deficiency promotes coexpression of myogenic and adipogenic programs in myoblasts. Mol Biol Cell (2005) 1.47
Role of Wnts in prostate cancer bone metastases. J Cell Biochem (2006) 1.46
LXRbeta is required for adipocyte growth, glucose homeostasis, and beta cell function. J Biol Chem (2005) 1.44
DNA methyltransferase 3b regulates nerve growth factor-induced differentiation of PC12 cells by recruiting histone deacetylase 2. Mol Cell Biol (2005) 1.41
Comment on: Screening for Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) among Endometrial Cancer Patients. Cancer Res (2007) 1.38
Risk factors for colorectal cancer in patients with multiple serrated polyps: a cross-sectional case series from genetics clinics. PLoS One (2010) 1.36
Role of de novo DNA methyltransferases and methyl CpG-binding proteins in gene silencing in a rat hepatoma. J Biol Chem (2002) 1.35
Epigenetic regulation of protein tyrosine phosphatases: potential molecular targets for cancer therapy. Cancer Gene Ther (2005) 1.34
Effects of Wnt signaling on brown adipocyte differentiation and metabolism mediated by PGC-1alpha. Mol Cell Biol (2005) 1.31
T-cell factor 4N (TCF-4N), a novel isoform of mouse TCF-4, synergizes with beta-catenin to coactivate C/EBPalpha and steroidogenic factor 1 transcription factors. Mol Cell Biol (2003) 1.29
Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol (2013) 1.27
Inhibitor of DNA binding 2 is a small molecule-inducible modulator of peroxisome proliferator-activated receptor-gamma expression and adipocyte differentiation. Mol Endocrinol (2008) 1.26
A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. Cancer Res (2009) 1.26
Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal. J Biol Chem (2011) 1.24
The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am J Pathol (2012) 1.20
Peptide mass mapping of acetylated isoforms of histone H4 from mouse lymphosarcoma cells treated with histone deacetylase (HDACs) inhibitors. J Am Soc Mass Spectrom (2005) 1.19
Physical and functional interaction of DNA methyltransferase 3A with Mbd3 and Brg1 in mouse lymphosarcoma cells. Cancer Res (2005) 1.17